Platelets and antiplatelet therapy in patients with coronary artery disease and diabetes

Seminars in Thrombosis and Hemostasis

Volumn 42, Issue 3, 2016, Pages 234-241

  Neergaard Petersen, Sos ^a   Hvas, Anne Mette ^a   Kristensen, Steen Dalby ^a   Grove, Erik Lerkevang ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

ADP receptor blockers; aspirin; coronary artery disease; diabetes mellitus; platelet aggregation; platelets

Indexed keywords

ACETYLSALICYLIC ACID; ADENOSINE DIPHOSPHATE RECEPTOR BLOCKER; ANTITHROMBOCYTIC AGENT; UNCLASSIFIED DRUG;

ARTICLE; BLOOD CLOTTING; BLOOD CLOTTING DISORDER; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DIABETIC PATIENT; DYSLIPIDEMIA; ENDOTHELIAL DYSFUNCTION; FIBRINOLYSIS; HIGH RISK PATIENT; HUMAN; HYPERCOAGULABILITY; HYPERGLYCEMIA; HYPERTENSION; MORBIDITY; OBESITY; PLATELET REACTIVITY; PRIORITY JOURNAL; RISK FACTOR; RISK REDUCTION; THROMBOCYTE; TREATMENT RESPONSE; BIOLOGICAL MODEL; BLOOD; DIABETES MELLITUS, TYPE 2; DRUG EFFECTS; PATHOPHYSIOLOGY; PHYSIOLOGY;

ASPIRIN; BLOOD COAGULATION; BLOOD PLATELETS; CORONARY ARTERY DISEASE; DIABETES MELLITUS, TYPE 2; HUMANS; HYPERTENSION; MODELS, CARDIOVASCULAR; PLATELET AGGREGATION INHIBITORS; RISK FACTORS;

EID: 84958818864     PISSN: 00946176     EISSN: 10989064     Source Type: Journal    
DOI: 10.1055/s-0036-1571308     Document Type: Article

References (96)

1. IDF Diabetes Atlas, sixth edition The International Diabetes Federation. Available at: http://www.idf.org/sites/default/files/DA-regional-factsheets-2014-FINAL.pdf. Accessed February 9, 2016
2. Grant P. J. Inflammatory, atherothrombotic aspects of type 2 diabetes. Curr Med Res Opin: 2005; 21 01 S5 S12
3. Haffner S. M., Lehto S., Rönnemaa T., Pyörälä K., Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med: 1998; 339 4 229 234
4. Schramm T. K., Gislason G. H., Kober L., et al. Diabetes patients requiring glucose-lowering therapy and nondiabetics with a prior myocardial infarction carry the same cardiovascular risk: a population study of 3.3 million people. Circulation: 2008; 117 15 1945 1954
5. American Diabetes Association (2) Classification and diagnosis of diabetes. Diabetes Care: 2015; 38 (Suppl): S8 S16
6. DeFronzo R. A., Abdul-Ghani M. Assessment and treatment of cardiovascular risk in prediabetes: impaired glucose tolerance and impaired fasting glucose. Am J Cardiol: 2011; 108 (3, Suppl) 3B 24B
7. Wascher T. C., Sourij H., Roth M., Dittrich P. Prevalence of pathological glucose metabolism in patients undergoing elective coronary angiography. Atherosclerosis: 2004; 176 2 419 421
8. Norhammar A., Tenerz A., Nilsson G., et al. Glucose metabolism in patients with acute myocardial infarction and no previous diagnosis of diabetes mellitus: a prospective study. Lancet: 2002; 359 9324 2140 2144
9. Cubbon R. M., Wheatcroft S. B., Grant P. J., et al. Evaluation of Methods and Management of Acute Coronary Events Investigators. Temporal trends in mortality of patients with diabetes mellitus suffering acute myocardial infarction: a comparison of over 3000 patients between 1995 and 2003. Eur Heart J: 2007; 28 5 540 545
10. Norhammar A., Lindbäck J., Rydén L., Wallentin L., Stenestrand U.; Register of Information and Knowledge about Swedish Heart Intensive Care Admission (RIKS-HIA). Improved but still high short- and long-term mortality rates after myocardial infarction in patients with diabetes mellitus: a time-trend report from the Swedish Register of Information and Knowledge about Swedish Heart Intensive Care Admission. Heart: 2007; 93 12 1577 1583
11. Fox C. S., Coady S., Sorlie P. D., et al. Trends in cardiovascular complications of diabetes. JAMA: 2004; 292 20 2495 2499
12. Krasopoulos G., Brister S. J., Beattie W. S., Buchanan M. R. Aspirin resistance and risk of cardiovascular morbidity: systematic review and meta-analysis. BMJ: 2008; 336 7637 195 198
13. Wisman P. P., Roest M., Asselbergs F. W., et al. Platelet-reactivity tests identify patients at risk of secondary cardiovascular events: a systematic review and meta-analysis. J Thromb Haemost: 2014; 12 5 736 747
14. Ferreiro J. L., Angiolillo D. J. Clopidogrel response variability: current status and future directions. Thromb Haemost: 2009; 102 1 7 14
15. Rydén L., Grant P. J., Anker S. D., et al. Authors/Task Force Members; ESC Committee for Practice Guidelines (CPG); Document Reviewers. ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the Task Force on diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and developed in collaboration with the European Association for the Study of Diabetes (EASD). Eur Heart J: 2013; 34 39 3035 3087
16. Freynhofer M. K., Bruno V., Wojta J., Huber K. The role of platelets in athero-thrombotic events. Curr Pharm Des: 2012; 18 33 5197 5214
17. Hoffman M., Monroe D. M. III. A cell-based model of hemostasis. Thromb Haemost: 2001; 85 6 958 965
18. Ajjan R. A., Grant P. J. Cardiovascular disease prevention in patients with type 2 diabetes: the role of oral anti-diabetic agents. Diab Vasc Dis Res: 2006; 3 3 147 158
19. Creager M. A., Lüscher T. F., Cosentino F., Beckman J. A. Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: Part I. Circulation: 2003; 108 12 1527 1532
20. Hess K., Grant P. J. Inflammation and thrombosis in diabetes. Thromb Haemost: 2011; 105 01 S43 S54
21. Ware J. A., Heistad D. D. Seminars in medicine of the Beth Israel Hospital, Boston. Platelet-endothelium interactions. N Engl J Med: 1993; 328 9 628 635
22. Sase K., Michel T. Expression of constitutive endothelial nitric oxide synthase in human blood platelets. Life Sci: 1995; 57 22 2049 2055
23. Anfossi G., Mularoni E. M., Burzacca S., et al. Platelet resistance to nitrates in obesity and obese NIDDM, and normal platelet sensitivity to both insulin and nitrates in lean NIDDM. Diabetes Care: 1998; 21 1 121 126
24. Davì G., Rini G. B., Averna M., et al. Thromboxane B2 formation and platelet sensitivity to prostacyclin in insulin-dependent and insulin-independent diabetics. Thromb Res: 1982; 26 5 359 370
25. Collet J. P., Allali Y., Lesty C., et al. Altered fibrin architecture is associated with hypofibrinolysis and premature coronary atherothrombosis. Arterioscler Thromb Vasc Biol: 2006; 26 11 2567 2573
26. Undas A., Kolarz M., Kopeć G., Tracz W. Altered fibrin clot properties in patients on long-term haemodialysis: relation to cardiovascular mortality. Nephrol Dial Transplant: 2008; 23 6 2010 2015
27. Dunn E. J., Ariëns R. A., Grant P. J. The influence of type 2 diabetes on fibrin structure and function. Diabetologia: 2005; 48 6 1198 1206
28. Dunn E. J., Philippou H., Ariëns R. A., Grant P. J. Molecular mechanisms involved in the resistance of fibrin to clot lysis by plasmin in subjects with type 2 diabetes mellitus. Diabetologia: 2006; 49 5 1071 1080
29. Fatah K., Hamsten A., Blombäck B., Blombäck M. Fibrin gel network characteristics and coronary heart disease: relations to plasma fibrinogen concentration, acute phase protein, serum lipoproteins and coronary atherosclerosis. Thromb Haemost: 1992; 68 2 130 135
30. Mills J. D., Ariëns R. A., Mansfield M. W., Grant P. J. Altered fibrin clot structure in the healthy relatives of patients with premature coronary artery disease. Circulation: 2002; 106 15 1938 1942
31. Undas A., Plicner D., Stepień E., Drwiła R., Sadowski J. Altered fibrin clot structure in patients with advanced coronary artery disease: a role of C-reactive protein, lipoprotein(a) and homocysteine. J Thromb Haemost: 2007; 5 9 1988 1990
32. Fatah K., Silveira A., Tornvall P., Karpe F., Blombäck M., Hamsten A. Proneness to formation of tight and rigid fibrin gel structures in men with myocardial infarction at a young age. Thromb Haemost: 1996; 76 4 535 540
33. Leander K., Blombäck M., Wallén H., He S. Impaired fibrinolytic capacity and increased fibrin formation associate with myocardial infarction. Thromb Haemost: 2012; 107 6 1092 1099
34. Kuliczkowski W., Witkowski A., Polonski L., et al. Interindividual variability in the response to oral antiplatelet drugs: a position paper of the Working Group on antiplatelet drugs resistance appointed by the Section of Cardiovascular Interventions of the Polish Cardiac Society, endorsed by the Working Group on Thrombosis of the European Society of Cardiology. Eur Heart J: 2009; 30 4 426 435
35. Aradi D., Storey R. F., Komócsi A., et al. Working Group on Thrombosis of the European Society of Cardiology. Expert position paper on the role of platelet function testing in patients undergoing percutaneous coronary intervention. Eur Heart J: 2014; 35 4 209 215
36. Vinik A. I., Erbas T., Park T. S., Nolan R., Pittenger G. L. Platelet dysfunction in type 2 diabetes. Diabetes Care: 2001; 24 8 1476 1485
37. Keating F. K., Sobel B. E., Schneider D. J. Effects of increased concentrations of glucose on platelet reactivity in healthy subjects and in patients with and without diabetes mellitus. Am J Cardiol: 2003; 92 11 1362 1365
38. Serebruany V., Pokov I., Kuliczkowski W., Chesebro J., Badimon J. Baseline platelet activity and response after clopidogrel in 257 diabetics among 822 patients with coronary artery disease. Thromb Haemost: 2008; 100 1 76 82
39. Neergaard-Petersen S., Hvas A. M., Grove E. L., Larsen S. B., Gregersen S., Kristensen S. D. The influence of haemoglobin A1c levels on platelet aggregation and platelet turnover in patients with coronary artery disease treated with aspirin. PLoS ONE: 2015; 10 7 e0132629
40. Watala C., Golanski J., Pluta J., et al. Reduced sensitivity of platelets from type 2 diabetic patients to acetylsalicylic acid (aspirin)-its relation to metabolic control. Thromb Res: 2004; 113 2 101 113
41. Angiolillo D. J., Fernandez-Ortiz A., Bernardo E., et al. Influence of aspirin resistance on platelet function profiles in patients on long-term aspirin and clopidogrel after percutaneous coronary intervention. Am J Cardiol: 2006; 97 1 38 43
42. Angiolillo D. J., Fernandez-Ortiz A., Bernardo E., et al. Platelet function profiles in patients with type 2 diabetes and coronary artery disease on combined aspirin and clopidogrel treatment. Diabetes: 2005; 54 8 2430 2435
43. Singla A., Antonino M. J., Bliden K. P., Tantry U. S., Gurbel P. A. The relation between platelet reactivity and glycemic control in diabetic patients with cardiovascular disease on maintenance aspirin and clopidogrel therapy. Am Heart J: 2009; 158 5 784.e1 784.e6
44. Vivas D., García-Rubira J. C., Bernardo E., et al. Effects of intensive glucose control on platelet reactivity in patients with acute coronary syndromes. Results of the CHIPS Study (Control de Hiperglucemia y Actividad Plaquetaria en Pacientes con Sindrome Coronario Agudo). Heart: 2011; 97 10 803 809
45. Lemkes B. A., Bähler L., Kamphuisen P. W., et al. The influence of aspirin dose and glycemic control on platelet inhibition in patients with type 2 diabetes mellitus. J Thromb Haemost: 2012; 10 4 639 646
46. Kuliczkowski W., Gasior M., Pres D., et al. Effect of glycemic control on response to antiplatelet therapy in patients with diabetes mellitus and ST-segment elevation myocardial infarction. Am J Cardiol: 2012; 110 3 331 336
47. Falcon C., Pfliegler G., Deckmyn H., Vermylen J. The platelet insulin receptor: detection, partial characterization, and search for a function. Biochem Biophys Res Commun: 1988; 157 3 1190 1196
48. Trovati M., Anfossi G. Influence of insulin and of insulin resistance on platelet and vascular smooth muscle cell function. J Diabetes Complications: 2002; 16 1 35 40
49. Kim J. A., Montagnani M., Koh K. K., Quon M. J. Reciprocal relationships between insulin resistance and endothelial dysfunction: molecular and pathophysiological mechanisms. Circulation: 2006; 113 15 1888 1904
50. Grove E. L., Hvas A. M., Kristensen S. D. Immature platelets in patients with acute coronary syndromes. Thromb Haemost: 2009; 101 1 151 156
51. Lordkipanidzé M. Platelet turnover in atherothrombotic disease. Curr Pharm Des: 2012; 18 33 5328 5343
52. Zuberi B. F., Akhtar N., Afsar S. Comparison of mean platelet volume in patients with diabetes mellitus, impaired fasting glucose and non-diabetic subjects. Singapore Med J: 2008; 49 2 114 116
53. Lee E. Y., Kim S. J., Song Y. J., Choi S. J., Song J. Immature platelet fraction in diabetes mellitus and metabolic syndrome. Thromb Res: 2013; 132 6 692 695
54. Demirtunc R., Duman D., Basar M., Bilgi M., Teomete M., Garip T. The relationship between glycemic control and platelet activity in type 2 diabetes mellitus. J Diabetes Complications: 2009; 23 2 89 94
55. Verdoia M., Schaffer A., Barbieri L., et al. Novara Atherosclerosis Study (NAS) group. Diabetes, glucose control and mean platelet volume: a single-centre cohort study. Diabetes Res Clin Pract: 2014; 104 2 288 294
56. Martin J. F., Kristensen S. D., Mathur A., Grove E. L., Choudry F. A. The causal role of megakaryocyte-platelet hyperactivity in acute coronary syndromes. Nat Rev Cardiol: 2012; 9 11 658 670
57. Freynhofer M. K., Gruber S. C., Grove E. L., Weiss T. W., Wojta J., Huber K. Antiplatelet drugs in patients with enhanced platelet turnover: biomarkers versus platelet function testing. Thromb Haemost: 2015; 114 3 459 468
58. Grove E. L., Hvas A. M., Mortensen S. B., Larsen S. B., Kristensen S. D. Effect of platelet turnover on whole blood platelet aggregation in patients with coronary artery disease. J Thromb Haemost: 2011; 9 1 185 191
59. Weyrich A. S., Schwertz H., Kraiss L. W., Zimmerman G. A. Protein synthesis by platelets: historical and new perspectives. J Thromb Haemost: 2009; 7 2 241 246
60. Kristensen S. D., Würtz M., Grove E. L., et al. Contemporary use of glycoprotein IIb/IIIa inhibitors. Thromb Haemost: 2012; 107 2 215 224
61. Antithrombotic Trialists' Collaboration Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ: 2002; 324 7329 71 86
62. American Diabetes Association (8) Cardiovascular disease and risk management. Diabetes Care: 2015; 38 (Suppl): S49 S57
63. Patrono C. Low-dose aspirin in primary prevention: cardioprotection, chemoprevention, both, or neither? Eur Heart J: 2013; 34 44 3403 3411
64. UK Prospective Diabetes Study (UKPDS) Group Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet: 1998; 352 9131 854 865
65. DiChiara J., Bliden K. P., Tantry U. S., et al. The effect of aspirin dosing on platelet function in diabetic and nondiabetic patients: an analysis from the aspirin-induced platelet effect (ASPECT) study. Diabetes: 2007; 56 12 3014 3019
66. Pulcinelli F. M., Biasucci L. M., Riondino S., et al. COX-1 sensitivity and thromboxane A2 production in type 1 and type 2 diabetic patients under chronic aspirin treatment. Eur Heart J: 2009; 30 10 1279 1286
67. Capodanno D., Patel A., Dharmashankar K., et al. Pharmacodynamic effects of different aspirin dosing regimens in type 2 diabetes mellitus patients with coronary artery disease. Circ Cardiovasc Interv: 2011; 4 2 180 187
68. Mortensen S. B., Larsen S. B., Grove E. L., Kristensen S. D., Hvas A. M. Reduced platelet response to aspirin in patients with coronary artery disease and type 2 diabetes mellitus. Thromb Res: 2010; 126 4 e318 e322
69. van Werkum J. W., Topcu Y., Postma S., et al. Effects of diabetes mellitus on platelet reactivity after dual antiplatelet therapy with aspirin and clopidogrel. Thromb Haemost: 2008; 99 3 637 639
70. Angiolillo D. J., Bernardo E., Sabaté M., et al. Impact of platelet reactivity on cardiovascular outcomes in patients with type 2 diabetes mellitus and coronary artery disease. J Am Coll Cardiol: 2007; 50 16 1541 1547
71. Henry P., Vermillet A., Boval B., et al. 24-hour time-dependent aspirin efficacy in patients with stable coronary artery disease. Thromb Haemost: 2011; 105 2 336 344
72. Christensen K. H., Grove E. L., Wurtz M., Kristensen S. D., Hvas A. M. Reduced antiplatelet effect of aspirin during 24 hours in patients with coronary artery disease and type 2 diabetes. Platelets: 2015; 26 3 230 235
73. Rocca B., Secchiero P., Ciabattoni G., et al. Cyclooxygenase-2 expression is induced during human megakaryopoiesis and characterizes newly formed platelets. Proc Natl Acad Sci U S A: 2002; 99 11 7634 7639
74. CAPRIE Steering Committee A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet: 1996; 348 9038 1329 1339
75. Wallentin L., Becker R. C., Budaj A., et al. PLATO Investigators. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med: 2009; 361 11 1045 1057
76. Wiviott S. D., Braunwald E., McCabe C. H., et al. TRITON-TIMI 38 Investigators. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med: 2007; 357 20 2001 2015
77. Valentine N., Van de Laar F. A., van Driel M. L. Adenosine-diphosphate (ADP) receptor antagonists for the prevention of cardiovascular disease in type 2 diabetes mellitus. Cochrane Database Syst Rev: 2012; 11 CD005449
78. Bernlochner I., Goedel A., Plischke C., et al. Impact of immature platelets on platelet response to ticagrelor and prasugrel in patients with acute coronary syndrome. Eur Heart J: 2015; 36 45 3202 3210
79. Snoep J. D., Hovens M. M., Eikenboom J. C., van der Bom J. G., Jukema J. W., Huisman M. V. Clopidogrel nonresponsiveness in patients undergoing percutaneous coronary intervention with stenting: a systematic review and meta-analysis. Am Heart J: 2007; 154 2 221 231
80. Schuette C., Steffens D., Witkowski M., et al. The effect of clopidogrel on platelet activity in patients with and without type-2 diabetes mellitus: a comparative study. Cardiovasc Diabetol: 2015; 14 15
81. Angiolillo D. J., Jakubowski J. A., Ferreiro J. L., et al. Impaired responsiveness to the platelet P2Y12 receptor antagonist clopidogrel in patients with type 2 diabetes and coronary artery disease. J Am Coll Cardiol: 2014; 64 10 1005 1014
82. Erlinge D., Varenhorst C., Braun O. O., et al. Patients with poor responsiveness to thienopyridine treatment or with diabetes have lower levels of circulating active metabolite, but their platelets respond normally to active metabolite added ex vivo. J Am Coll Cardiol: 2008; 52 24 1968 1977
83. 12 receptor signalling pathway in patients with type 2 diabetes mellitus and coronary artery disease. Thromb Haemost: 2011; 105 4 730 732
84. James S., Angiolillo D. J., Cornel J. H., et al. PLATO Study Group. Ticagrelor vs. clopidogrel in patients with acute coronary syndromes and diabetes: a substudy from the PLATelet inhibition and patient Outcomes (PLATO) trial. Eur Heart J: 2010; 31 24 3006 3016
85. Wiviott S. D., Braunwald E., Angiolillo D. J., et al. TRITON-TIMI 38 Investigators. Greater clinical benefit of more intensive oral antiplatelet therapy with prasugrel in patients with diabetes mellitus in the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-Thrombolysis in Myocardial Infarction 38. Circulation: 2008; 118 16 1626 1636
86. Malmberg K. Prospective randomised study of intensive insulin treatment on long term survival after acute myocardial infarction in patients with diabetes mellitus. DIGAMI (Diabetes Mellitus, Insulin Glucose Infusion in Acute Myocardial Infarction) Study Group. BMJ: 1997; 314 7093 1512 1515
87. Davì G., Catalano I., Averna M., et al. Thromboxane biosynthesis and platelet function in type II diabetes mellitus. N Engl J Med: 1990; 322 25 1769 1774
88. Ray K. K., Seshasai S. R., Wijesuriya S., et al. Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials. Lancet: 2009; 373 9677 1765 1772
89. Gerstein H. C., Miller M. E., Ismail-Beigi F., et al. ACCORD Study Group. Effects of intensive glycaemic control on ischaemic heart disease: analysis of data from the randomised, controlled ACCORD trial. Lancet: 2014; 384 9958 1936 1941
90. Gerstein H. C., Miller M. E., Byington R. P., et al. Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med: 2008; 358 24 2545 2559
91. UK Prospective Diabetes Study (UKPDS) Group Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet: 1998; 352 9131 837 853
92. Perneby C., Wallén N. H., Rooney C., Fitzgerald D., Hjemdahl P. Dose- and time-dependent antiplatelet effects of aspirin. Thromb Haemost: 2006; 95 4 652 658
93. Bonten T. N., Saris A., van Oostrom M. J., et al. Effect of aspirin intake at bedtime versus on awakening on circadian rhythm of platelet reactivity. A randomised cross-over trial. Thromb Haemost: 2014; 112 6 1209 1218
94. Grove E. L., Storey R. F., Kristensen S. D. Can we improve the efficacy of low-dose aspirin? Thromb Haemost: 2014; 112 6 1077 1078
95. Storey R. F., Angiolillo D. J., Patil S. B., et al. Inhibitory effects of ticagrelor compared with clopidogrel on platelet function in patients with acute coronary syndromes: the PLATO (PLATelet inhibition and patient Outcomes) PLATELET substudy. J Am Coll Cardiol: 2010; 56 18 1456 1462
96. Ferreiro J. L., Angiolillo D. J. Diabetes and antiplatelet therapy in acute coronary syndrome. Circulation: 2011; 123 7 798 813